Fundamentals-based quality & risk · not a recommendation
Astec LifeSciences Limited scores 11/100 (Avoid) on the Orion Score — poor business quality (9), poor growth (11) and poor balance-sheet safety (16). A fundamentals-based quality & risk score, not a buy/sell recommendation.
Risk checks
Forensic accounting
Piotroski F = fundamental health (0–9, higher is better) · Altman Z = bankruptcy / distress risk · Beneish M = earnings-manipulation check
Technical / Momentum
Price Trend
55/100
Technical momentum companion — separate from the fundamentals-based Orion Score.
Unlock with Pro
Upgrade →Q4 FY2026
Revenue & Profit in ₹ Crores
| Quarter | Revenue | Net Profit | OPM | EPS |
|---|---|---|---|---|
| Q4 2026 | ₹158.62 | ₹-7.76 | -1.6% | ₹-3.48 |
| Q3 2026 | ₹124.72 | ₹-15.7 | -5.8% | ₹-7.04 |
| Q1 2026 | ₹91.08 | ₹-33.04 | -24.7% | ₹-16.72 |
| Q4 2025 | ₹119.53 | ₹-16.09 | -5.1% | ₹-8.20 |
| Q3 2025 | ₹93.86 | ₹-40.38 | -18.3% | ₹-20.59 |
Revenue & Profit in ₹ Crores (Yearly)
| Year | Revenue | Net Profit | EBITDA | OPM |
|---|---|---|---|---|
| FY 2025 | ₹381.3 | ₹-134.75 | ₹-61 | -28.8% |
| FY 2024 | ₹458.18 | ₹-46.93 | ₹-0.64 | -9.1% |
| FY 2023 | ₹628.17 | ₹25.56 | ₹88.76 | 6.9% |
| FY 2022 | ₹676.57 | ₹89.86 | ₹164.18 | 17.8% |
Top companies in the same sector by market cap
| Company | Mkt Cap | P/E | ROCE | ROE | D/E | OPM |
|---|---|---|---|---|---|---|
| ASTEC ★ | ₹1,536 Cr | — | -11.17% | -25.84% | 1.15x | -1.65% |
| AETHER | ₹19,918 Cr | 90.08 | 11.68% | 9.38% | 0.19x | 21.06% |
| ATUL | ₹18,360 Cr | 27.11 | 10.56% | 11.53% | 0.03x | 12.07% |
| CHAMBLFERT | ₹18,180 Cr | 9.31 | 19.66% | 20.45% | 0.10x | 5.92% |
| ANURAS | ₹14,436 Cr | 82.66 | 8.65% | 5.76% | 0.41x | 18.15% |
| ACI | ₹6,512 Cr | 60.98 | 6.58% | 5.55% | 0.24x | 6.94% |
All values in ₹ Crores
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total Assets | ₹881.42 | ₹974.93 | ₹979.41 | ₹896.76 |
| Equity | ₹234.75 | ₹369.29 | ₹419.36 | ₹396.5 |
| Total Debt | ₹554.54 | ₹493.89 | ₹341.18 | ₹279.37 |
| Cash | ₹0.58 | ₹0.47 | ₹0.47 | ₹0.55 |
| Net Debt | ₹553.97 | ₹493.42 | ₹340.71 | ₹278.82 |
| Working Capital | ₹-24.57 | ₹1.33 | ₹-27.35 | ₹25.09 |
Q1 FY2027
Quarter-over-Quarter Trend
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Q1 FY2027 | 73.33% ↓ | 1.66% | 1.36% | 23.65% ↑ |
| Q4 FY2026 | 73.37% ↑ | 1.66% ↑ | 1.36% ↓ | 23.61% ↓ |
| Q3 FY2026 | 71.97% ↓ | 0.04% ↑ | 3.17% ↓ | 24.82% ↑ |
| Q2 FY2026 | 72.42% ↑ | 0% ↓ | 4.01% ↓ | 23.57% ↓ |
| Q1 FY2026 | 70.87% | 0.02% ↓ | 4.26% ↓ | 24.84% ↑ |
| Q4 FY2025 | 70.87% ↑ | 0.25% ↓ | 4.34% ↓ | 24.53% ↓ |
| Q3 FY2025 | 66.74% | 1.2% ↑ | 5.4% ↑ | 26.64% ↓ |
| Q2 FY2025 | 66.74% | 0.53% | 4.5% | 28.2% |
No recent corporate actions
4 mutual fund schemes
Ask: "Is Astec LifeSciences Limited stock a good buy right now?" — Get RSI, MACD, ROCE + AI recommendation
Analyse with OrionGet free stock analysis, market insights, and investment ideas delivered to your inbox.
No spam. Unsubscribe anytime.
Astec LifeSciences Limited is listed on the NSE under the Chemicals sector, Pesticides & Agrochemicals industry. ISIN: INE563J01010. Track live share price, technical analysis, RSI, MACD, PE ratio, and smart money holdings on VestAI — India's AI-powered stock analysis platform.